Inhibition of HBV replication by VPS4B and its dominant negative mutant VPS4B-K180Q in vivo.
	    		
	    			
	    			
		        		
			        		
		        		
			        
		   		
		   		
	    	
    	 
    	
   		
        
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Jianbo, XIA
			        		
			        		;
		        		
		        		
		        		
			        		Weipeng, WANG
			        		
			        		;
		        		
		        		
		        		
			        		Lei, LI
			        		
			        		;
		        		
		        		
		        		
			        		Zhi, LIU
			        		
			        		;
		        		
		        		
		        		
			        		Min, LIU
			        		
			        		;
		        		
		        		
		        		
			        		Dongliang, YANG
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
            
            
            	- From:
	            		
	            			Journal of Huazhong University of Science and Technology (Medical Sciences)
	            		
	            		 2012;32(3):311-6
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:English
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	This study examined the anti-hepatitis B virus (HBV) effect of wild-type (WT) vacuolar protein sorting 4B (VPS4B) and its dominant negative (DN) mutant VPS4B-K180Q in vivo in order to further explore the relationship between HBV and the host cellular factor VPS4. VPS4B gene was amplified from Huh7 cells by RT-PCR and cloned into the eukaryotic expression vector pXF3H. Then, the VPS4B plasmid and the VPS4B-K180Q mutation plasmid were constructed by using the overlap extension PCR site-directed mutagenesis technique. VPS4B and HBV vectors were co-delivered into mice by the hydrodynamic tail-vein injection to establish HBV vector-based models. Quantities of HBsAg and HBeAg in the mouse sera were determined by ElectroChemiLuminescence (ECL). HBV DNA in sera was measured by real-time quantitative PCR. Southern blot analysis was used to assay the intracellular HBV nuclear capsid-related DNA, real-time quantitative PCR to detect the HBV-related mRNA and immunohistochemical staining to observe the HBcAg expression in the mouse liver tissues. Our results showed that VPS4B and its mutant VPS4B-K180Q could decrease the levels of serum HBsAg, HBeAg and HBV-DNA. In addition, the HBV DNA replication and the mRNA level of HBV in the liver tissues of treated mice could be suppressed by VPS4B and VPS4B-K180Q. It was also found that VPS4B and VPS4B-K180Q had an ability to inhibit core antigen expression in the infected mouse liver. Furthermore, the anti-HBV effect of mutant VPS4B-K180Q was more potent than that of wild-type VPS4B. Taken together, it was concluded that VPS4B and its DN mutant VPS4B-K180Q have anti-HBV effect in vivo, which helps develop molecular therapeutic strategies for HBV infection.